Evidence map›Paper›PMID 27080082›Full record

ReviewPhysiology & behavior2016

Hypoglycemia unawareness prevention: Targeting glucagon production.

Willis K Samson, Lauren M Stein, Mollisa Elrick, Alison Salvatori, Grant Kolar, John A Corbett, Gina L C Yosten

Abstract readReview
In one paragraph

Review in Physiology & behavior, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Willis K SamsonDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO 63104, United States. Electronic address: samsonwk@slu.edu.
Lauren M SteinDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO 63104, United States.
Mollisa ElrickDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO 63104, United States.
Alison SalvatoriDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO 63104, United States.
Grant KolarDepartment of Pathology, Saint Louis University School of Medicine, St. Louis, MO 63104, United States.
John A CorbettDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, United States.
Gina L C YostenDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO 63104, United States.
Saint Louis University · USMedical College of Wisconsin · US

Funding

BIOCHEMICAL MECHANISM OF BETA-CELL DESTRUCTIONR01DK052194 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CORBETT, JOHN A · 1998 to 2025
$8.8M
Pharmacological Sciences Training GrantT32GM008306 · NIGMS · SAINT LOUIS UNIVERSITY · PI EGAN, TERRANCE M, WALKER, JOHN K. · 1990 to 2020
$3.6M
Angiotensin Receptor Regulation By Upstream Short Open Reading FramesR01HL121456 · NHLBI · GEORGETOWN UNIVERSITY · PI SAMSON, WILLIS K., SANDBERG, KATHRYN L · 2014 to 2017
$3.1M
PHYSIOLOGY OF THE PROLACTIN RELEASING PEPTIDESR01HL066023 · NHLBI · SAINT LOUIS UNIVERSITY · PI SAMSON, WILLIS K. · 2001 to 2010
$2.0M
NHLBI NIH HHS R01 HL066023NHLBI NIH HHS R01 HL121456NIDDK NIH HHS R01 DK052194NIGMS NIH HHS T32 GM008306
6 · The paper itself

Abstract

Insulin-dependent individuals with diabetes are at risk for a severe hypoglycemic event that may predispose them to several repeat episodes during which the normal counter regulatory mechanisms that protect against hypoglycemia fail to be activated. This state of hypoglycemia unawareness is characterized by a failure of glucagon release, preventing mobilization of endogenous glucose stores from the liver. We describe the discovery of a novel hormone, produced in pancreatic delta cells, which stimulates glucagon production and release, particularly under low glucose conditions. We hypothesize that this hormone, called neuronostatin, may be effective as a co-therapy with insulin to prevent repeated, potentially fatal episodes of recurrent hypoglycemia.

Indexed as

AnimalsGlucagonHumansHypoglycemiaInsulinPeptide HormonesGlucagonInsulinneuronostatin, humanPeptide HormonesGlucagonHypoglycemiaInsulinNeuronostatin

Identifiers

PMID27080082
PMCPMC4899234
OpenAlexW2335754498

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.